Heron Therapeutics Inc. (NASDAQ:HRTX) shares, rose in value on Friday, June 16, with the stock price down by -4.20% to the previous day’s close as strong demand from buyers drove the stock to $1.25.
Actively observing the price movement in the recent trading, the stock is buoying the session at $1.31, falling within a range of $1.2573 and $1.325. Referring to stock’s 52-week performance, its high was $5.62, and the low was $1.07. On the whole, HRTX has fluctuated by 0.40% over the past month.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it’s about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that HRTX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
6 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 6 recommend it as a Buy and 0 called the HRTX stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of HRTX currently trading nearly 1.66% and -33.95% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 39.85, while the 7-day volatility ratio is showing 9.34% which for the 30-day chart, stands at 9.79%. Furthermore, Heron Therapeutics Inc. (HRTX)’s beta value is 0.94, and its average true range (ATR) is 0.13. The company’s stock has been forecasted to trade at an average price of $7.92 over the course of the next 52 weeks, with a low of $5.50 and a high of $10.00. Based on these price targets, the low is -340.0% off current price, whereas the price has to move -700.0% to reach the yearly target high. Additionally, analysts’ median price of $8.00 is likely to be welcomed by investors because it represents a decrease of -540.0% from the current levels.
A comparison of Heron Therapeutics Inc. (HRTX) with its peers suggests the former has fared considerably weaker in the market. HRTX showed an intraday change of -4.20% in today’s session so far, and over the past year, it shrunk by -50.78%%. In comparison, Ligand Pharmaceuticals Incorporated (LGND) has moved lower at -1.06% today and is up 53.15% over the past 12 months. On the other hand, the price of Pacira BioSciences Inc. (PCRX) has fallen -0.05% today. The stock, however, is off -26.12% from where it was a year ago. Additionally, there is a loss of -0.43% for Surmodics Inc. (SRDX) in recent trading while the stock has seen an overall depriciation of -31.29%% over the past year. Other than that, the overall performance of the S&P 500 during the today’s session so far shows that it lost -0.05%. Meanwhile, the Dow Jones Industrial Slipped by -0.04%.
Data on historical trading for Heron Therapeutics Inc. (NASDAQ:HRTX) indicates that the trading volumes over the past 10 days have averaged 2.14 million and over the past 3 months, they’ve averaged 2.62 million. According to company’s latest data on outstanding shares, there are 119.25 million shares outstanding.
Nearly 0.20% of Heron Therapeutics Inc.’s shares belong to company insiders and institutional investors own 102.55% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 23.38 million shares as on May 30, 2023, resulting in a short ratio of 8.18. According to the data, the short interest in Heron Therapeutics Inc. (HRTX) stood at 19.53% of shares outstanding as of May 30, 2023; the number of short shares registered in Apr 27, 2023 reached 22.3 million. The stock has fallen by -49.80% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the HRTX stock heading into the next quarter.